VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ARGX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ARGXargenx SE
$981.33$63.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ARGX logo

argenx SE

ARGX
NASDAQ · Immunology Biotech
$981.33
At close - Nov 12, 4:00 PM EST - USD
Market Cap$63.67B
P/E50.0x
52W High$1072.75
Volume384.56K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q4

VYVGART Scale-Up Drives Margins; Working Capital Tests Cash Quality

argenx's revenue expanded from roughly $790.7M in 2025Q1 to $3.2B in 2025Q4, and operating margin moved from -23.3% in 2024Q2 to 30.1% in 2026Q2, suggesting the VYVGART franchise has reached commercial scale with a gross margin steady near 88% to 90%.

GrowthAccelerating
ProfitabilityStrong
ValuationReview
TechnicalsHealthy
Explore valuation models
MARKET ACTION

ARGX price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

9/12 Beats

EPS beat 9 of last 12 quarters

02

Valuation risk

+41% Peers

P/E is 41% above peer median

03

Market leadership

RS 71 · Avg

Average momentum (RS Rating: 71)

04

Healthy Uptrend

Uptrend

Price > 50DMA > 200DMA

Next CatalystEstimated earnings · Oct 30
01

Build the investment case

Start with the evidence for owning the stock and the risks that can break the thesis.

EXECUTIVE THESIS

The Investment Case

Full Analysis
Fundamental Trajectory

Revenue scaled several-fold while gross margin held between 88% and 90%, and operating margin recovered to 30.1% in 2026Q2 from negative levels in 2024, though the 46% sequential revenue decline into 2026Q4 warrants close monitoring of run-rate durability.

Analyst Consensus+15.5% target
Buy(36 analysts)
32 Buy4 Hold0 Sell

The Bull Case

Upside Catalysts

Blockbuster therapy success

VYVGART generated over $4.1 billion in 2025, nearly doubling year-on-year, showcasing strong revenue growth.

Clinical data efficacy

New clinical data presented at the 2026 American Academy of Neurology meeting demonstrated VYVGART's efficacy in treating ocular myasthenia gravis and broader MG subtypes.

Global market presence

argenx SE operates in key international markets including the United States, Japan, China, and the Netherlands, enhancing its revenue potential.

The Bear Case

Key Downside Risks

Market performance

Price History →

Trailing total returns as of 11/13/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ARGX+16.83%
S&P 500 (^GSPC)+10.82%
1-Year Return
ARGX+10.28%
S&P 500 (^GSPC)+10.79%
3-Year Return
ARGX+100.21%
S&P 500 (^GSPC)+72.69%
5-Year Return
ARGX+216.93%
S&P 500 (^GSPC)+61.91%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
50.0x
Forward P/EExpansion
34.5x
EV/EBITDA100th %ile
55.7x
FCF YieldCash Flow
1.3%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
50.0x
48.1x
100th· High
EV/EBITDA
55.7x
48.1x
100th· High
Price/FCF
75.4x
65.8x
100th· High
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$420.95-57.1%
Base (Fair)$748.10-19.3%
Bull$959.74-2.2%
$420.95 Bear$748.10 Base$959.74 Bull
Current Market Price: $981.33
Trades at a 31.2% premium to Base DCF ($748.10)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$4.15B+89.6% YoY
Net income FY25
$1.29B+55.1% YoY
Free cash flow FY25
$844M+659.0% YoY
Operating margin FY25
25.4%+26.4 pts YoY
ROIC (FY25)19.9%
Avg ROIC 5Y-12.2%
ROE (FY25)20.2%
Piotroski Score4 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate9/12 (82%)
Revenue Beat Rate5/12 (45%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q3 2026Latest
Jul 30, 2026
$7.80+4.8%
vs $7.44
$2.8B+69.6%
vs $1.7B
Q2 2026
May 7, 2026
$5.90+14.3%
vs $5.16
$3.2B+121.8%
vs $1.4B
Q1 2026
Feb 26, 2026
$8.02+48.2%
vs $5.41
$2.4B+79.6%
vs $1.3B
Q4 2025
Oct 30, 2025
$5.18+18.5%
vs $4.37
$948M-25.7%
vs $1.3B
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
The Motley Fool·4d ago
3 Reasons Argenx Could Be a Top Biotech Stock for the Next Decade

Argenx's Vyvgart franchise addresses about 28,000 patients today, with the company targeting 60,000 by 2030. The biotech is solidly profitable, with Q3 revenue up 54% and $3.7 billion in cash to fund growth.

GlobeNewsWire·4d ago
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines

Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion

GlobeNewsWire·4d ago
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities

Amsterdam, the Netherlands, November 9, 2026, 07:00 CET – argenx (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced a definitive agreement to acquire Unnatural Products, Inc. (UNP), adding a macrocyclic peptide discovery engine to its immunology innovation capabilities. argenx, which already holds a minority stake in UNP, will acquire all remaining shares in a transaction valuing UNP at up to approximately $1.15 billion across upfront and milestone payments. This acquisition expands the ways argenx can pursue novel biology and develop oral or long-acting medicines for people living with serious immune-mediated diseases.

GlobeNewsWire·6d ago
argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis

ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis subtype with no approved therapies Consistent, clinically meaningful treatment effect in DM, demonstrating improvements in muscle strength and skin disease activity November 7, 2026, 10:00 AM ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, today announced that data from the Phase 3 ALKIVIA study demonstrating rapid and sustained improvement with VYVGART ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in patients with autoimmune myositis will be featured in a late-breaking oral presentation (#LB24) at the American College of Rheumatology (ACR) Convergence 2026 on November 11, 2026, from 9:15-9:30 a.m. ET. Combined IMNM and DM population: Primary and key secondary endpoints met The study met its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) patient population, demonstrating that patients treated with efgartigimod achieved a statistically significant and clinically meaningful 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 versus placebo (p=0.0011; 48.0 vs 32.6).

Filtered for argenx SEMore Headlines
04

Compare before deciding

Benchmark ARGX against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for argenx SE (ARGX)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ARGX logoARGXargenx SECurrent
$981.33$63.67B49.9989.64%31.11%20.15%—
RARE logoRAREUltragenyx Pharmaceutical Inc.
$16.27$1.6B-3.1720.13%-71.78%——
ALNY logoALNYAlnylam Pharmaceuticals, Inc.
$156.65$20.91B7.9465.19%54.34%159.72%—
SRPT logoSRPTSarepta Therapeutics, Inc.
$16.01$1.69B114.9315.58%0.75%1.04%—
BMRN logoBMRNBioMarin Pharmaceutical Inc.
$56.70$10.96B-574.4712.87%-0.52%-0.31%—
IONS logoIONSIonis Pharmaceuticals, Inc.
$27.31$4.54B-8.0033.87%-64.64%-110.84%—

Compare ARGX vs Peers

argenx SE (ARGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RARE

Most directly comparable listed peer for ARGX.

Scale Benchmark

vs JNJ

Larger-name benchmark to compare ARGX against a more recognizable public peer.

Peer Set

Compare Top 5

vs RARE, ALNY, SRPT, BMRN

Get notified when ARGX posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ARGX Frequently Asked Questions

argenx SE (ARGX) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is argenx SE's revenue?

argenx SE (ARGX) reported $4.15B in revenue in fiscal year 2025. That is 284775% more than the $1.5M of fiscal year 2011.

How fast is argenx SE growing?

argenx SE (ARGX) grew revenue by 89.6% in fiscal year 2025, compared with the prior fiscal year.

Is ARGX profitable?

Yes. argenx SE (ARGX) earned $1.29B in net income in fiscal year 2025 (a 31.1% net margin).

Dividend & Returns
What is ARGX's return on equity?

argenx SE (ARGX) had a return on equity (ROE) of 20.2% in fiscal year 2025. That is well above the market's typical 10-15%.

What is argenx SE's free cash flow?

argenx SE (ARGX) generated $844.3M in free cash flow in fiscal year 2025.

What if you invested $1,000 in ARGX back in 2011?

Total return calculator · dividends reinvested · 15+ years of data

See returns →